Float Short %

3.27

Margin Of Safety %

Put/Call OI Ratio

0.56

EPS Next Q Diff

0.25

EPS Last/This Y

1.27

EPS This/Next Y

Price

2.3

Target Price

Analyst Recom

Performance Q

248.48

Relative Volume

0.12

Beta

1.39

Ticker: SPRO

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-04	SPRO	2.91	0.64	0.00	12828
2025-07-07	SPRO	2.9	0.64	0.00	12829
2025-07-08	SPRO	2.94	0.65	0.01	12814
2025-07-09	SPRO	3.05	0.64	0.01	12898
2025-07-10	SPRO	2.85	0.60	0.01	13420
2025-07-11	SPRO	2.82	0.56	0.06	14057
2025-07-14	SPRO	2.64	0.52	0.03	14925
2025-07-15	SPRO	2.49	0.52	0.83	14892
2025-07-16	SPRO	2.47	0.54	0.10	15143
2025-07-17	SPRO	2.48	0.54	0.20	15198
2025-07-18	SPRO	2.37	0.54	0.48	15207
2025-07-21	SPRO	2.33	0.69	0.01	9859
2025-07-22	SPRO	2.43	0.62	0.31	10556
2025-07-23	SPRO	2.38	0.62	0.09	10670
2025-07-24	SPRO	2.36	0.62	0.00	10689
2025-07-25	SPRO	2.34	0.61	0.00	10758
2025-07-28	SPRO	2.3	0.58	0.00	11089
2025-07-29	SPRO	2.19	0.56	0.04	11285
2025-07-30	SPRO	2.18	0.56	0.00	11355
2025-07-31	SPRO	2.32	0.56	0.00	11426
2025-08-01	SPRO	2.31	0.56	0.04	11446
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-04	SPRO	2.91	3.0	-	-0.84
2025-07-07	SPRO	2.90	3.0	-	-0.84
2025-07-08	SPRO	2.94	3.0	-	-0.84
2025-07-09	SPRO	3.04	3.0	-	-0.84
2025-07-10	SPRO	2.84	3.0	-	-0.84
2025-07-11	SPRO	2.81	3.0	-	-0.84
2025-07-14	SPRO	2.64	3.0	-	-0.84
2025-07-15	SPRO	2.49	3.0	-	-0.84
2025-07-16	SPRO	2.48	3.0	-	-0.84
2025-07-17	SPRO	2.48	3.0	-	-0.84
2025-07-18	SPRO	2.38	3.0	-	-0.84
2025-07-21	SPRO	2.32	3.0	-	-0.84
2025-07-22	SPRO	2.43	3.0	-	-0.84
2025-07-23	SPRO	2.38	3.0	-	-0.84
2025-07-24	SPRO	2.35	3.0	-	-0.84
2025-07-25	SPRO	2.33	3.0	-	-0.84
2025-07-28	SPRO	2.30	3.0	-	-0.84
2025-07-29	SPRO	2.20	3.0	-	-0.84
2025-07-30	SPRO	2.17	3.0	-	-0.84
2025-07-31	SPRO	2.32	3.0	-	-0.84
2025-08-01	SPRO	2.30	-	-	0.00
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-04	SPRO	-1.59	-4.80	4.33
2025-07-07	SPRO	-1.59	-4.80	4.33
2025-07-08	SPRO	-1.59	-4.80	4.33
2025-07-09	SPRO	-1.59	-4.80	4.33
2025-07-10	SPRO	-1.59	-4.80	4.33
2025-07-11	SPRO	-1.59	-4.80	4.56
2025-07-14	SPRO	-1.59	-4.49	4.56
2025-07-15	SPRO	-1.59	-4.49	4.56
2025-07-16	SPRO	-1.59	-4.49	4.56
2025-07-17	SPRO	-1.59	-4.49	4.56
2025-07-18	SPRO	-1.59	-4.49	4.56
2025-07-21	SPRO	-1.59	-3.90	4.56
2025-07-22	SPRO	-1.59	-3.90	4.56
2025-07-23	SPRO	-1.59	-3.90	4.56
2025-07-24	SPRO	-1.59	-3.90	4.56
2025-07-25	SPRO	-1.59	-3.90	3.27
2025-07-28	SPRO	-1.59	-3.90	3.27
2025-07-29	SPRO	-1.59	-3.90	3.27
2025-07-30	SPRO	-1.59	-3.90	3.27
2025-07-31	SPRO	-1.59	-3.90	3.27
2025-08-01	SPRO	-1.59	-3.90	3.27
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.25

Avg. EPS Est. Current Quarter

-0.32

Avg. EPS Est. Next Quarter

Insider Transactions

-1.59

Institutional Transactions

-3.9

Beta

1.39

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

90.3

Max Drawdown 5-Year %

-97.5

Target Price

P/E

Forward P/E

4.79

PEG

P/S

4.54

P/B

3.8

P/Free Cash Flow

EPS

-1.28

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-246.49

Relative Volume

0.12

Return on Equity vs Sector %

-230.1

Return on Equity vs Industry %

-211.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Spero Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 32

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today

news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance

stock history SPRO – Spero Therapeutics, Inc. invest stock market

stock prices SPRO premarket after hours

ticker SPRO fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SPRO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y